RCM
PEARW

Radcliffe Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Radcliffe Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-183,465
Closed -$1.82M – 1100
2021
Q3 		$1.82M Hold
183,465
– – 0.05% 509
2021
Q2 		$1.81M Buy
+183,465
New +$160K 0.06% 533

Other funds holding PEARW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Radcliffe Capital Management's PEARW Position: Q4 2021 in Review

Radcliffe Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q4 2021, closing a stake of 183,465 shares — an estimated $1.82M sold.

Radcliffe Capital Management first reported a position in PEARW in Q2 2021 and held it in 2 quarters. The position peaked at $1.82M in Q3 2021. 44 funds tracked by Wall St. Rank hold PEARW as of Q4 2021.

  • Radcliffe Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 183,465 Pear Therapeutics, Inc. Warrant shares in Q4 2021, an estimated $1.82M.
  • Radcliffe Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 2 quarters.
  • Radcliffe Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $1.82M in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q4 2021.

Based on Radcliffe Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.